01
Cash & equivalents decreased 12.7%
Cash & equivalents changed -12.7% from the comparable as-filed period.
$87.7M→$76.5MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTAtea Pharmaceuticals, Inc.'s latest supported as-filed period reports revenue of $351.4M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -12.7% from the comparable as-filed period.
Net income changed +11.4% from the comparable as-filed period.
Operating income changed +15.1% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
AVIR · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-347021SEC ↗8-KAug 12, 2026Period Aug 12, 20260001193125-26-346888SEC ↗4Jun 23, 2026Period Jun 18, 20260001193125-26-279728SEC ↗4Jun 23, 2026Period Jun 18, 20260001193125-26-279726SEC ↗4Jun 23, 2026Period Jun 18, 20260001193125-26-279723SEC ↗4Jun 23, 2026Period Jun 18, 20260001193125-26-279721SEC ↗4Jun 23, 2026Period Jun 18, 20260001193125-26-279719SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 18, 2026Filed Jun 23, 2026 | Lucidi BrunoDirector | Option ExerciseDirect | 29,600 | $0 | $0 | Form 4 ↗ |
| Jun 18, 2026Filed Jun 23, 2026 | Lucidi BrunoDirector | Option ExerciseDirect | 29,600 | $0 | $0 | Form 4 ↗ |
| Jun 18, 2026Filed Jun 23, 2026 | Lucidi BrunoDirector | Grant Or AwardDirect | 26,700 | $0 | $0 | Form 4 ↗ |
| Jun 18, 2026Filed Jun 23, 2026 | Lucidi BrunoDirector | Grant Or AwardDirect | 37,700 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -12.8% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Stock-based compensation changed -27.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-279718